A Phase 3 Randomized Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)

Brief description of study

This is a research study involving the drug pembrolizumab. The purpose of this study is to: o See if the study drug, pembrolizumab, in combination with chemotherapy and surgery is more effective than placebo (a look-alike product with no active ingredients) with chemotherapy and surgery. This will be measured by tissue samples that are taken during surgery as well as imaging performed at different time points. o Test the safety of the study drugs, pembrolizumab in combination with chemotherapy and surgery o See how well your body handles pembrolizumab compared to placebo in combination with chemotherapy and surgery o See if pembrolizumab helps patients have a better quality of life o See if pembrolizumab helps patients live longer


Clinical Study Identifier: s18-01572
ClinicalTrials.gov Identifier: NCT03924856
Principal Investigator: Arjun Vasant Balar.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.